US Edition
Massalia Therapeutics launches to advance novel treatments for complex conditions
Summary by pharmatimes.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
All
Left
Center
Right
Massalia Therapeutics kicks off with seed financing - European Biotechnology Magazine
French biotech firm Massalia Therapeutics SA has been launched, backed by seed funding from Landmark Bioventures, the company founders and their network. The company claims to have an IND-ready, first-in-class drug candidate poised to target both cancer and fibrosis. The post Massalia Therapeutics kicks off with seed financing appeared first on European Biotechnology Magazine.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
